Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001641172-25-021070
Filing Date
2025-07-25
Accepted
2025-07-25 19:48:18
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 10092
2 EX-99.6 ex99-6.htm EX-99.6 87901
  Complete submission text file 0001641172-25-021070.txt   99609
Mailing Address 15 INDEPENDENCE BOULEVARD, SUITE #210 WARREN NJ 07059
Business Address 15 INDEPENDENCE BOULEVARD, SUITE #210 WARREN NJ 07059 646-807-8832
Tevogen Bio Holdings Inc. (Subject) CIK: 0001860871 (see all company filings)

EIN.: 981597194 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-93039 | Film No.: 251152763
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O TEVOGEN BIO HOLDINGS INC. 15 INDEPENDENCE BLVD, SUITE 210 WARREN NJ 07059
Business Address
Saadi Ryan H. (Filed by) CIK: 0002011728 (see all company filings)

Type: SCHEDULE 13D/A